Highlights
Scientific Article
unige:90077 
 |
Anticoagulation orale et pharmacogénétique : perspectives pour la pratique clinique |
|
| Authors | ||
| Published in | Revue médicale suisse. 2007, vol. 3, no. 124, p. 2030-2036 | |
| Abstract | Single nucleotide polymorphisms (SNPs) in genes encoding cytochrome P450 enzyme 2C9 (CYP2C9) and Vitamin K epoxide reductase subunit I (VKORC1) make a significant contribution to the inter-individual variability in the maintenance dose of vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon). Doses requirements in CYP2C9*2 and CYP2C9*3 heterozygotes are reduced by 8-16% and 20-36%, respectively. SNP g-1639a in VKORC1 is also associated with vitamin K antagonists dosage since heterozygotes ga and homozygotes aa require respectively 21-28% and 27-56% less warfarin or acenocoumarol than homozygotes gg. CYP2C9 and VKORC1 account for up to half the variability in vitamin K antagonists requirements and incorporating genotying data for these two genes into dosing algorithms could lead to a safer anticoagulation therapy. | |
| Keywords | Anticoagulants/pharmacology — Aryl Hydrocarbon Hydroxylases/genetics — Cytochrome P-450 CYP2C9 — Humans — Mixed Function Oxygenases/genetics — Pharmacogenetics — Polymorphism, Single Nucleotide — Vitamin K/antagonists & inhibitors — Vitamin K Epoxide Reductases | |
| Identifiers | PMID: 17955831 | |
| Full text |
This document has no fulltext available yet, but you can contact its author by using the form below.
|
|
| Structures | ||
| Research group | Groupe Desmeules Jules (pharmacologie/toxicologie) (567) | |
| Citation (ISO format) | BENUSIGLIO, Patrick Raphaël et al. Anticoagulation orale et pharmacogénétique : perspectives pour la pratique clinique. In: Revue médicale suisse, 2007, vol. 3, n° 124, p. 2030-2036. https://archive-ouverte.unige.ch/unige:90077 |
210 hits 
0 download 
Contact an author
Update